<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">VORICONAZOLE</span><br/>(vor-i-con'a-zole)<br/><span class="topboxtradename">Vfend<br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antibiotic</span>; <span class="classification">azole antifungal</span><br/><b>Prototype: </b>Fluconazole<br/><b>Pregnancy Category: </b>D<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>50 mg, 200 mg tablets; 200 mg injection</p>
<h1><a name="action">Actions</a></h1>
<p>Inhibits fungal cytochrome P-450 enzymes used for an essential step in fungal ergosterol biosynthesis. The subsequent loss
         of ergosterol in the fungal cell wall may be responsible for the antifungal activity of voriconazole.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Voriconazole is active against <i>Aspergillus fumigatus</i> as well as <i>A. flavus, A. niger,</i> and <i>A. terreus</i>. Variable activity against <i>Scedosporium apiospermum</i> and <i>Fusarium</i> sp., including <i>Fusarium solani,</i> has been seen.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of invasive <i>Aspergillosis,</i> esophageal candidiasis, candidemia in nonneutropenic patients and disseminated skin infections, and abdomen, kidney, bladder
         wall, and wound infections due to Candida.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to voriconazole; intravenous voriconazole should be avoided in moderate or severe renal impairment
         (Cl<sub>cr</sub>
</p><h1><a name="precaution">Cautious Use</a></h1>
<p>Mild to moderate hepatic cirrhosis, hepatitis, hepatic disease; renal disease, renal impairment; ocular disease; hypersensitivity
         to other azole antifungal agents such as fluconazole; children &gt;2 y and 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Aspergillosis</span><br/><span class="rdage">Adult/</span><span class="rdage">Geriatric:</span> <span class="rdroute">IV</span> 6 mg/kg q12h day 1, then 4 mg/kg q12h. May reduce to 3 mg/kg q12h if not tolerated <span class="rdroute">PO</span>
<i>&gt;40 kg</i>, 400 mg q12h day 1, then 200 mg q12h. May increase to 300 mg q12h if inadequate response. <i> 400 mg q12h day 1, then 100 mg q12h. May increase to 150 mg q12h if inadequate response.<br/><br/><span class="indicationtitle">Esophageal Candidiasis</span><br/><span class="rdage">Adult/</span><span class="rdage">Geriatric:</span> <span class="rdroute">PO</span>
<i>&gt;40 kg,</i> 200 mg q12h for a minimum of 14 d and for at least 7 d after resolution of symptoms; <i> 100 mg q12h for a minimum of 14 d and for at least 7 d after resolution of symptoms.<br/><br/><span class="indicationtitle">Dose Adjustment for Concomitant Fosphenytoin or Phenytoin</span><br/><span class="rdage">Adult/</span><span class="rdage">Geriatric:</span> <span class="rdroute">IV</span> 6 mg/kg q12h day 1, then 5 mg/kg q12h. <span class="rdroute">PO</span>
<i>&gt;40 kg</i>, 400 mg q12h day 1, then 400 mg q12h. <i> 400 mg q12h day 1, then 200 mg q12h<br/></i></i></i></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give at least 1 h before or 1 h following a meal.</li>
<li>Manufacturer recommendation: maintenance dose to be halved in patients with mild to moderate hepatic cirrhosis. Consult physician.</li>
<li>Store tablets at 15°30° C (59°86° F).</li>
</ul>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><ul>
<li>IV voriconazole should be avoided in patients with moderate or severe renal impairment.</li>
</ul>
<p><span class="routemethod">PREPARE:</span> <span class="methodtype">Intermittent:</span> Use a 20 mL syringe to reconstitute powder with exactly 19 mL of sterile water for injection to yield 10 mg/mL. Discard vial
                  if a vacuum does not pull the diluent into vial. Shake until completely dissolved. From an IV infusion bag of NS, D5W, D5/NS,
                  D5/.45NS, RL or other suitable diluent withdraw and discard a volume of IV solution adequate to produce final voriconazole
                  concentration within the range of 0.55 mg/mL. Inject the calculated dose of voriconazole into the IV bag. Discard unused
                  voriconazole. Infuse IV solution immediately.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Intermittent:</span> Infuse over 12 h at a maximum rate of 3 mg/kg per h. DO NOT give a bolus dose.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span> Do not dilute with <b>sodium bicarbonate;</b> do not mix with any other drugs. <span class="incompattype">Y-site:</span> Do not infuse with other drugs. 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store unreconstituted vials at 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Peripheral edema, fever, chills. <span class="typehead">CNS:</span> Headache, hallucinations, dizziness. <span class="typehead">CV:</span> Tachycardia, hypotension, hypertension, vasodilation. <span class="typehead">GI:</span> Nausea, vomiting, abdominal pain, abnormal LFTs, diarrhea, cholestatic jaundice, dry mouth. <span class="typehead">Metabolic:</span> Increased alkaline phosphatase, AST, ALT, hypokalemia, hypomagnesemia. <span class="typehead">Skin:</span> Rash, pruritus. <span class="typehead">Special Senses:</span>
<span class="speceff-common">Abnormal vision (enhanced brightness, blurred vision, or color vision changes),</span> photophobia. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Due to significant increased toxicity or decreased activity, the following drugs are <u>contraindicated</u> with voriconazole: <span class="classification">barbiturates</span>, <b>carbamazepine,</b>
<b>efavirenz,</b>
<span class="classification"> ergot alkaloids</span>, <b>pimozide,</b>
<b>quinidine,</b>
<b>rifabutin,</b>
<b>sirolimus;</b>
<b>fosphenytoin,</b>
<b>phenytoin,</b>
<b>rifampin,</b>
<b> ritonavir</b> may significantly decrease voriconazole levels. <span class="classification">protease inhibitors</span> (except <b>indinavir</b>) may increase voriconazole toxicity; voriconazole may increase the toxicity of <span class="classification">benzodiazepines</span>, <b>cyclosporine,</b>
<span class="classification">protease inhibitors</span> (except <b>indinavir</b>), <span class="classification">nonnucleoside reverse transcriptase inhibitors</span>, <b>omeprazole,</b>
<b>tacrolimus,</b>
<b>vinblastine,</b>
<b>vincristine,</b>
<b>warfarin;</b>
<span class="classification">nonnucleoside reverse transcriptase inhibitors</span> may increase or decrease voriconazole levels. <span class="typehead">Food:</span> Absorption reduced with high-fat meals. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> 96% absorbed PO. Has a non-linear pharmacokinetic profile, a small change in dose may cause a large change in serum levels.
      Steady state not achieved until day 56 if no loading dose is given. <span class="typehead">Peak:</span> 12 h. <span class="typehead">Metabolism:</span> Metabolized in liver by (and is an inhibitor of) CYP3A4, 2C9 and 2C19. <span class="typehead">Elimination:</span> Primarily excreted in urine. <span class="typehead">Half-Life:</span> 6 h6 d depending on dose. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor visual acuity, visual field, and color perception if treatment continues beyond 28 d.</li>
<li>Withhold drug and notify physician if skin rash develops.</li>
<li>Monitor cardiovascular status especially with preexisting CV disease.</li>
<li>Lab tests: Monitor baseline and periodic LFTs including bilirubin; patients who develop abnormal liver function tests during
            therapy should be monitored for the development of more severe hepatic injury. Monitor frequently renal function tests, especially
            serum creatinine. Monitor periodic CBC with platelet count, Hct &amp; Hgb, serum electrolytes, alkaline phosphatase, blood glucose,
            and lipid profile.
         </li>
<li>Concurrent drugs: Monitor PT/INR closely with warfarin as dose adjustments of warfarin may be needed. Monitor frequently blood
            glucose levels with sulfonylurea drugs as reduction in the sulfonylurea dosage may be needed. Monitor for and report any of
            the following: S&amp;S of rhabdomyolysis in patient receiving a statin drug; prolonged sedation in patient receiving a benzodiazepine;
            S&amp;S of heart block, bradycardia, or CHF in patient receiving a calcium channel blocker.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Use reliable means of birth control to prevent pregnancy. If you suspect you are pregnant, contact physician immediately.</li>
<li>Do not drive at night while taking voriconazole as the drug may cause blurred vision and photophobia.</li>
<li>Do not drive or engage in other potentially hazardous activities until reaction to drug is known.</li>
<li>Avoid strong, direct sunlight while taking voriconazole.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>